CERC...Found that as well. Also did a bit more digging. This is a second Ph II trial. First one at lower dose failed, so they're trying again with a higher dose. Safety profile is good.
Certainly risk here but may run a bit as there is some chatter this compound could be better in that it more directly targets MDD.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.